Tatva Chintan Pharma Chem Ltd - Stock Valuation and Financial Performance

BSE: 543321 | NSE: TATVA | Chemicals | Small Cap

Tatva Chintan Pharma Share Price

1,265.50 -22.50 -1.75%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Tatva Chintan Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Tatva Chintan Pharma Chem stock performance -

mw4me loader
P/E Ratio (SA):
79.46
Market Cap:
2,960.3 Cr.
52-wk low:
1,063.4
52-wk high:
1,888.1

Is Tatva Chintan Pharma Chem Ltd an attractive stock to invest in?

1. Is Tatva Chintan Pharma Chem Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Tatva Chintan Pharma Chem Ltd is a average quality company.

2. Is Tatva Chintan Pharma Chem Ltd undervalued or overvalued?

The key valuation ratios of Tatva Chintan Pharma Chem Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Tatva Chintan Pharma Chem Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Tatva Chintan Pharma Chem Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Tatva Chintan Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Tatva Chintan Pharma Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 20.1%18.2%17.4%23.2%11.7%17.1%21.3%22.5%22.8%8%-
Value Creation
Index
0.40.30.30.7-0.20.20.50.60.6-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 80.410289.9109129203254291428403404
Sales YoY Gr.-26.4%-11.5%21%19%56.8%25.1%14.7%46.9%-5.8%-
Adj EPS 4.82.83.685.110.317.724.141.620.215.9
YoY Gr.--41.5%29.2%120.9%-36.3%100.8%72.8%35.7%72.8%-51.4%-
BVPS (₹) 14.412.516.124.730.239.65780.6211.5227.7308.3
Adj Net
Profit
5.25.77.316.110.320.635.648.392.144.837
Cash Flow from Ops. 3.35.38.724.312.97.924.618.919.823.7-
Debt/CF from Ops. 6.33.72.41.94.49.83.74.86.17.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 19.6%25.5%16.7%-5.8%
Adj EPS 17.3%31.7%4.5%-51.4%
BVPS35.9%49.8%58.7%7.7%
Share Price - - - -23.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
39.827.625.439.318.629.436.73529.29.25.9
Op. Profit
Mgn %
13.411.116.523.715.717.121.122.524.814.316.8
Net Profit
Mgn %
6.55.68.114.87.910.21416.621.511.19.2
Debt to
Equity
1.30.80.70.90.910.80.60.30.3-
Working Cap
Days
134141178175189152156191199252147
Cash Conv.
Cycle
4340475061718510611716673

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.66%

Return on Equity has declined versus last 3 years average to 5.90%

Net Profit has been subdued in last 3 years 4.48%

Sales growth is not so good in last 4 quarters at 6.62%

Latest Financials - Tatva Chintan Pharma Chem Ltd.

Standalone Consolidated
TTM EPS (₹) 15.9 16.1
TTM Sales (₹ Cr.) 404 420
BVPS (₹.) 308.3 312.4
Reserves (₹ Cr.) 698 707
P/BV 4.11 4.05
PE 79.46 78.53
From the Market
52 Week Low / High (₹) 1063.35 / 1888.05
All Time Low / High (₹) 1063.35 / 2975.55
Market Cap (₹ Cr.) 2,960
Equity (₹ Cr.) 23.4
Face Value (₹) 10
Industry PE 49.3

Management X-Ray of Tatva Chintan Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Tatva Chintan Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales8010290109129203254291428403
Operating Expenses 70907583109170201226322348
Manufacturing Costs71051122033366554
Material Costs5064485268115130148196222
Employee Cost 4876101621243139
Other Costs 891514291818173033
Operating Profit 111115262033536510655
Operating Profit Margin (%) 13.4%11.1%16.5%23.7%15.7%16.4%20.8%22.5%24.8%13.6%
Other Income 01155015116
Interest 2222344459
Depreciation 12224457810
Exceptional Items 000001000-4
Profit Before Tax 8812271826445910339
Tax 3341066987-2
Profit After Tax 56717122035519640
PAT Margin (%) 6.5%5.6%8.3%15.9%9.2%9.9%13.8%17.6%22.4%10.0%
Adjusted EPS (₹)4.82.83.78.65.910.117.425.643.318.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%20%5%11%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 162532506180114162469505
Share Capital 4888888202222
Reserves 121724415372106142447483
Minority Interest0000000000
Debt2119214656717976106160
Long Term Debt7441720323927134
Short Term Debt141617293640404992156
Trade Payables14191518252231474432
Others Liabilities 213941420354946
Total Liabilities 536571123146187245320667743

Fixed Assets

Gross Block161822227073122139186232
Accumulated Depreciation4681013711182736
Net Fixed Assets121314135667111120160196
CWIP 0252710651051231
Investments 0011211111
Inventories1113182024315968161151
Trade Receivables19252029364551906290
Cash Equivalents 3241881610417539
Others Assets810101510239275935
Total Assets 536571123146187245320667743

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 3592413825192024
PBT 8812271826445910339
Adjustment 233207871016
Changes in Working Capital -4-3-160-20-20-38-75-23
Tax Paid -3-3-4-10-5-6-7-10-18-8
Cash Flow From Investing Activity -3-5-8-25-24-17-40-21-197-101
Capex -3-5-7-25-24-10-48-21-89-203
Net Investments 00000-770-11297
Others 00-11001055
Cash Flow From Financing Activity 0011511710-523538
Net Proceeds from Shares 040000002110
Net Proceeds from Borrowing 000001313-9-13-13
Interest Paid -1-100-3-4-4-4-5-8
Dividend Paid 0000000-40-4
Others 1-3115481134264
Net Cash Flow 10115-108-6-658-40
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)40.3527.7825.8642.2521.6128.7636.0337.1630.438.31
ROCE (%)30.2226.7827.4238.9820.2622.1926.7827.8825.797.49
Asset Turnover Ratio1.91.861.431.20.961.221.171.030.870.57
PAT to CFO Conversion(x)0.60.831.291.411.080.40.710.370.210.6
Working Capital Days
Receivable Days65728376917269896568
Inventory Days384058616350658098141
Payable Days78961311181177575968562

Tatva Chintan Pharma Chem Ltd Stock News

Tatva Chintan Pharma Chem Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Tatva Chintan Pharma on 12-Apr-2024 16:59 is ₹1,265.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Tatva Chintan Pharma stood at ₹2,960.3.
The latest P/E ratio of Tatva Chintan Pharma as of 12-Apr-2024 16:59 is 79.46.
The latest P/B ratio of Tatva Chintan Pharma as of 12-Apr-2024 16:59 is 4.11.
The 52-week high of Tatva Chintan Pharma is ₹1,888.1 and the 52-week low is ₹1,063.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tatva Chintan Pharma is ₹404.1 ( Cr.) .

About Tatva Chintan Pharma Chem Ltd

The company is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes. For instance, its SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.

The company continuously strive to improve its processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of its products, it serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from company’s customers in India, it also export its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.

Business area of the company

The company is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.

Awards, accreditations or recognitions

  • 2006: Received ISO 9001:2015 certification for manufacturing facility at Ankleshwar.
  • 2015: Appreciation certificate from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for Company’s contribution to the revenue and voluntary compliance with tax laws.
  • 2016: Accorded the status of a two star export house from the Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India.
  • 2017: Received ISO 14001:2015 and BS OHSAS 18001:2007 certification for our manufacturing facility at Ankleshwar.
  • 2018: Received ISO 9001: 2015 certification for manufacturing facilities at Ankleshwar and Dahej.
  • 2018: Received ISO 14001: 2015 and BS OHSAS 18001:2007 certification for manufacturing facility at Dahej.
  • 2019: R&D facility recognized by the Department of Scientific and Industrial Research, Government of India for the purpose of availing customs duty exemption.
  • 2020: Received ISO 14001:2015 and 45001:2018 certification for manufacturing facility at Ankleshwar.

Major events and milestones

  • 1996: Incorporation of the company.
  • 2004: Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at our Ankleshwar Manufacturing Facility.
  • 2007: Expansion of manufacturing capacity at Ankleshwar Manufacturing Facility.
  • 2011: Commenced commercial manufacturing of SDAs.
  • 2013: Attained turnover of Rs 500.00 million.
  • 2015: Attained turnover of Rs 1 billion.
  • 2015: Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of Company.
  • 2015: Set up warehousing facility in Netherlands.
  • 2017: Set up Dahej Manufacturing Facility.
  • 2018: Set up R&D facility in Vadodara.
  • 2019: Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of Company.
  • 2020: Completion of ‘Together for Sustainability’ audit.
  • 2020: Conversion of Ankleshwar Manufacturing Facility to a ‘zero liquid effluent discharge facility’.
  • 2020: Attained total revenue of Rs 2 billion.
  • 2020: Increase in manufacturing capacity at our Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of our Company from 160 KL and 10 Assembly Lines to 280 KL and 13 Assembly Lines.


Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.